Vaccines are among the most cost-effective health interventions against pathogens and other infectious diseases, saving millions of lives annually while improving quality of life for countless others. Growing global demand, however, poses severe challenges for vaccine manufacturers. Each new pathogen or outbreak adds to the variety of vaccine types and manufacturing methods needed, preventing establishment of robust processing templates that could improve overall effectiveness, safety, and affordability. Manufacturers must instead develop customized approaches that extend the boundaries of life science, while at the same time accelerating production of desperately needed vaccines with efficiency and cost-effectiveness.
From a manufacturing perspective, many factors are critical to accelerating vaccine production and meeting performance goals. These include predictable scale-up, optimal upstream productivity, robust impurity removal, maximized downstream recovery, speed to clinic, patient safety, and regulatory compliance. Achieving process improvements can drive success for all of the vaccine development platforms described below, but innovative technologies and a high level of application expertise are required.
Brochure: Vaccine Bioprocessing Handbook
Brochure: Enabling Vaccines Production - Solving Challenges Together
Biopharmaceutical Applications Guide
Workflow: mRNA Manufacturing and Formulation. Products. Services. Expertise
Brochure: Enabling Solutions for Vaccines and Viral Therapies
Webinar: Make it Right – Best Practices for mRNA Manufacturing
Webinar: Unlocking the Potential of mRNA Vaccines and Therapeutics: A Manufacturing Perspective
Webinar: Process Development Guidance for AAV and Lentivirus Manufacturing Based on Cost Modeling
Webinar: Sf-RVN Cell Line and CD Media Platform: A Production Platform for VLP and AAV
Article: Manufacturing Strategies for mRNA Vaccines and Therapeutics
White Paper: Developing an Accelerated and More Cost-Effective Single-Use Adenoviral Vector Vaccine Manufacturing Process
White Paper: How Pandemics and Outbreaks Have Influenced the Adoption of Single-use Vaccine Manufacturing
Brochure: Flexible Manufacturing of Vaccine
Webinar: Re-imagining Vaccine Manufacturing to Address Global Health Challenges
Infographics Manufacturing Costs
White Paper: Vaccine Manufacturing - Collaboration Helps to Overcome Vaccine Process Challenges
Webinar: Scalable Purification of Plasmid DNA for use in Vaccine Manufacturing
eBook: Plasmid DNA Downstream Process
Application Note: Scalable Purification of Plasmid DNA for use in Vaccine Manufacturing
White Paper: Downstream Process Intensification for Virus Purification Using Membrane Chromatography
Webinar: Downstream Process Intensification for Virus Purification Using Membrane Chromatography
White Paper: Filtration Strategies for Optimal Development and Purification of a Foot and Mouth Disease Virus
Application Note: Eshmuno CMX on Glycovariant Separation Including for COVID-19
Application Note: Optimizing Downstream Processing for an Inactivated Rabies Vaccine
Application Note: Effect of Benzonase® Endonuclease Addition to Purification of Sabin Polio Virus Type 3
Webinar: Racing to Develop COVID-19 Vaccines and Therapies that Meet Regulatory Expectations
Webinar: Accelerating COVID-19 Therapies: How a Streamlined Biosafety Strategy Can Get You to Clinic Faster
By attenuating viruses to render them harmless while retaining their immunogenic profile, virus-based vaccines offer quick immunity, activate all phases of the immune system, and provide durable long-term immunity. The manufacturing process for each viral-based vaccine (VBV) is different, dictated by virus shape, size, nature, physico-chemical behavior, stability, and host specificity. An important challenge is to keep the attenuated virus live while maintaining the infective potential of the viral vaccine throughout downstream processing and formulation, until it is administered to healthy individuals.
A virus-like particle is a biological nanoparticle consisting of the protective protein shell of a virus without its genome. Mimicking the overall structure of virus particles but lacking infectious genetic material, they represent an appealing model for vaccine development. VLPs can be produced by methods such as mammalian cell culture, insect cell culture, and bacterial and yeast-based systems. While these systems can result in good production yields, purification requires particular attention. The challenge is to develop a scalable upstream process, together with clarification steps and effective purification, while ensuring product quality and reproducibility.
Viral vectors are a promising platform for vaccine development, inducing cell-mediated immunity against complex diseases such as Ebola, RSV, COVID-19, and other emerging threats. They also offer quick-response potential to repurpose a single virus production template for multiple diseases. However, viral vector processes can pose challenges: improving yield to meet patient demand, maintaining biosafety testing standards for product characterization, potency and safety, as well as streamlining time-consuming production to enhance commercial readiness and accelerate therapy to-market. Manufacturers that overcome these challenges can capitalize on viral vector platform opportunities, while improving the response to global health challenges.
Plasmid DNA (pDNA) is an important component of viral vector or vaccines therapies. pDNA is also used as the starting material for mRNA vaccines.
These circular DNA molecules can be used as therapeutic transgene, to code for the viral capsid or as the vaccine itself. DNA vaccines have been approved for use in animals and have been developed against the SARS-CoV-2 virus.
mRNA vaccines are rapidly developing vaccine type and have clearly demonstrated that they are opening a new era in vaccinology. Nucleic acids are based either on DNA formed from a fermentation process and, on messenger RNA (mRNA), which are synthesized in in vitro systems. They induce or promote an immune response against a large number of potential pathogens. These RNA vaccines are growing in popularity because of their quick turnaround time and cost-effective production of large quantities in the event of an outbreak or pandemic. They are also resilient and offer long shelf life under a variety of storage conditions.
Conjugated polysaccharide (CPS) vaccines are used globally, particularly in children and the developing world. They offer lifesaving protection against a variety of bacterial infections, including pneumonia, Haemophilus influenzae type b (Hib), and meningitis. Because polysaccharide antigens are not very immunogenic in their native state, chemical conjugation with an immunogenic carrier protein is a critical step. CPS vaccine production requires a complex, multi-step downstream purification process that can pose severe challenges for manufacturers under pressure to maximize yield and reduce costs. To keep CPS vaccines affordable for developing countries, state-of-the-art technologies and process design are essential for fast, cost-effective production that also meets specifications.
Toxoid and whole bacteria vaccines induce immunity in a similar manner as CPS vaccines, which also utilize inactivated toxoids or bacteria via chemical conjugation. While these platforms are generally regarded as safe, there are process-related challenges with endotoxin removal and, as with any process, the goal of optimizing recovery and yield. Such challenges must be overcome during process development and implementation in order to assure high-quality product.